Walking Fish Therapeutics is developing a platform that utilizes B cell activation to enhance immune responses against diseases. This technology aims to improve therapeutic outcomes for patients with immune-related conditions by leveraging the natural capabilities of B cells.
Funding
$23M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
NVFounders
Product
Problem
Current immunotherapies often struggle to effectively target and eliminate cancer cells, particularly in solid tumors, due to limited penetration and immunosuppressive microenvironments. Traditional approaches may also lack the specificity needed to avoid off-target effects and systemic toxicity.
Solution
Walking Fish Therapeutics is pioneering a B-cell-based immunotherapy platform designed to overcome the limitations of existing cancer treatments. The company engineers B cells to produce antibodies directly within the tumor microenvironment, enhancing local immune responses and promoting targeted cancer cell destruction. This approach aims to improve therapeutic efficacy while minimizing systemic side effects by leveraging the natural ability of B cells to traffic to and persist within tumors. The platform has the potential to address a wide range of cancers, including those that are resistant to current immunotherapies.
Target Audience
The primary target audience includes patients with solid tumors and hematological malignancies who have failed to respond to or are ineligible for existing therapies, as well as oncologists and hematologists seeking more effective and targeted treatment options.
Features
- B cell engineering platform for generating tumor-specific antibody-secreting cells
- Enhanced tumor penetration and localized antibody delivery
- Potential for long-term immune surveillance and durable responses
- Minimized systemic toxicity through targeted antibody production